Data / Drug companies / Synergy Health Ast, LLC
Synergy Health Ast, LLC: 30 products in the FDA NDC directory, labeler code 71161
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Synergy Health Ast, LLC (labeler code 71161) lists 30 products in the FDA National Drug Code Directory. By type: 30 drugs for further processing. Its main marketing category is drugs for further processing. The newest product started marketing on March 11, 2026.
The request: Watch Synergy Health Ast, LLC (FDA labeler code 71161): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 71161
- Products in commercial distribution
- 30
- Packages
- 31
- Finished drugs by generic name
- 0
- Prescription products
- 0
- Over the counter products
- 0
- Started marketing in the last 12 months
- 3
- Earliest marketing start
- June 15, 2000
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Drugs for further processing | 30 | 100% |
Products by type
| Type | Products | Share |
|---|---|---|
| Drugs for further processing | 30 | 100% |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Implant | 6 | 20% |
| Injection, powder, for suspension | 5 | 16.7% |
| Injection, powder, for suspension, extended release | 4 | 13.3% |
| Powder | 4 | 13.3% |
| Injection, powder, lyophilized, for suspension | 4 | 13.3% |
| Injection | 3 | 10% |
| Injection, suspension, extended release | 3 | 10% |
| Gel | 1 | 3.3% |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Leuprolide acetate | 71161-157 | Injection, suspension, extended release | Drugs for further processing | March 11, 2026 |
| Leuprolide acetate | 71161-156 | Injection, suspension, extended release | Drugs for further processing | March 9, 2026 |
| Leuprolide acetate | 71161-155 | Injection, suspension, extended release | Drugs for further processing | March 9, 2026 |
| Cabotegravir and rilpivirine | 71161-154 | Powder | Drugs for further processing | March 13, 2025 |
| Birch triterpenes | 71161-152 | Gel | Drugs for further processing | February 22, 2024 |
| Travoprost intracameral | 71161-151 | Implant | Drugs for further processing | December 13, 2023 |
| Etonogestrel | 71161-147 | Implant | Drugs for further processing | June 1, 2021 |
| Bimatoprost | 71161-153 | Implant | Drugs for further processing | March 4, 2020 |
| Afamelanotide | 71161-146 | Implant | Drugs for further processing | December 31, 2019 |
| Pasireotide | 71161-127 | Injection, powder, for suspension | Drugs for further processing | July 12, 2018 |
| Pasireotide | 71161-130 | Injection, powder, for suspension | Drugs for further processing | June 29, 2018 |
| Mometasone furoate | 71161-133 | Implant | Drugs for further processing | February 1, 2018 |
| Talc | 71161-150 | Powder | Drugs for further processing | November 1, 2017 |
| Talc | 71161-149 | Powder | Drugs for further processing | November 1, 2017 |
| Triamcinolone acetonide | 71161-135 | Injection, powder, for suspension, extended release | Drugs for further processing | October 6, 2017 |
| Triptorelin | 71161-106 | Injection, powder, lyophilized, for suspension | Drugs for further processing | September 8, 2017 |
| Talc | 71161-148 | Powder | Drugs for further processing | August 1, 2017 |
| Pasireotide | 71161-129 | Injection, powder, for suspension | Drugs for further processing | December 15, 2014 |
| Pasireotide | 71161-128 | Injection, powder, for suspension | Drugs for further processing | December 15, 2014 |
| Pasireotide | 71161-126 | Injection, powder, for suspension | Drugs for further processing | December 15, 2014 |
| Triptorelin pamoate | 71161-105 | Injection, powder, lyophilized, for suspension | Drugs for further processing | March 11, 2010 |
| Olanzapine pamoate | 71161-144 | Injection, powder, for suspension, extended release | Drugs for further processing | December 11, 2009 |
| Olanzapine pamoate | 71161-143 | Injection, powder, for suspension, extended release | Drugs for further processing | December 11, 2009 |
| Olanzapine pamoate | 71161-142 | Injection, powder, for suspension, extended release | Drugs for further processing | December 11, 2009 |
| Dexamethasone | 71161-138 | Implant | Drugs for further processing | September 1, 2009 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.